© The Financial Times Ltd 2015 FT and 'Financial Times' are trademarks of The Financial Times Ltd.
As of Aug 25, 2015, the consensus forecast amongst 36 polled investment analysts covering AstraZeneca plc advises investors to hold their position in the company. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Jul 31, 2009. The previous consensus forecast advised that AstraZeneca plc would outperform the market.
|Last year||3 months ago||2 months ago||4 weeks ago||Latest|
Share price forecast information is not available for AstraZeneca PLC. View Full Financials
In 2014, AstraZeneca PLC reported a dividend of 2.80 USD, equaling last years dividend. The 32 analysts covering the company expect dividends of 2.81 USD for the upcoming fiscal year, maintaining dividends from this year. View Full Financials
|Div growth (TTM)||0.00%|
On Jul 30, 2015, AstraZeneca plc reported 2nd quarter 2015 earnings of 1.20 per share. This result exceeded the 1.05 consensus of the 15 analysts covering the company and under-performed last year's 2nd quarter results by 7.69 %.
The next earnings announcement is expected on Nov 05, 2015. View Full Interim Financials
|Average growth rate||+1.59 %|
AstraZeneca plc reported annual 2014 earnings of 4.28 per share on Feb 05, 2015. View Full Annual Financials
|Average growth rate||-9.98 %|
AstraZeneca PLC had 2nd quarter 2015 revenues of 6bn. This bettered the 6bn consensus of the 17 analysts covering the company. This was 2.28 % below the prior year's 2nd quarter results. View Full Interim Financials
|Average growth rate||-0.43 %|
AstraZeneca PLC had revenues for the full year 2014 of 26bn. This was 1.49% above the prior year's results. View Full Annual Financials
|Average growth rate||-5.59 %|